


PHARMACEUTICAL 2020



Y-mAbs Therapeutics Inc. Rank 45 of 358





PHARMACEUTICAL 2020



Y-mAbs Therapeutics Inc. Rank 45 of 358



The relative strengths and weaknesses of Y-mAbs Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Y-mAbs Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 114% points. The greatest weakness of Y-mAbs Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 223%, being 187% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	211,955
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,586
Liabilities, Non-Current	1,956
Other Assets	2,359
Other Compr. Net Income	43
Other Expenses	0
Other Liabilities	1,921
Other Net Income	1,976
Other Revenues	0
Property and Equipment	2,052
Research and Development	63,492
Selling, General and Administrative Expense	19,512

Output Variable	Value in 1000 USD
Assets	216,366
Liabilities	17,463
Expenses	83,004
Revenues	0
Stockholders Equity	198,903
Net Income	-81,028
Comprehensive Net Income	-81,006
Economic Capital Ratio	223%

